Avacta (LSE:AVCT) Reports Clinical Progress and Board Changes Ahead of AGM

Avacta Therapeutics plc (LSE:AVCT),a UK-based clinical-stage life sciences company, provided a business update ahead of its 2025 Annual General Meeting, outlining recent progress across its oncology pipeline and key corporate developments.

Team Kalkine | 02 July 2025

Spire Healthcare Earns Double BUY Ratings with Up to 31% Upside Potential

Highlights

Team Kalkine | 26 June 2025

Avacta Therapeutics Reports FY24 Results, Sharpens Focus on Oncology Drug Development

Highlights

Team Kalkine | 06 June 2025

Dr. Martens Charts Path to Profit Recovery in FY26 Following Strategic Reset

Highlights

Team Kalkine | 05 June 2025

hVIVO Faces Contract Cancellation and Trial Postponement Amid Sector Uncertainty

hVIVO plc (LSE:HVO)is a UK-based contract research organisation specialising in human challenge clinical trials. The company also offers laboratory and early-phase clinical trial services through its subsidiaries, including CRS and Venn.

Team Kalkine | 30 May 2025

ANGLE Reports FY2024 Results with Narrowed Loss and Continued Focus on Pharma Collaborations

ANGLE plc (LSE:AGL),a UK-based liquid biopsy company specializing in circulating tumour cell (CTC) solutions, has released its audited preliminary financial results for the year ended 31 December 2024. The company reported a reduction in operating loss alongside a revenue increase, following operational restructuring and …

Team Kalkine | 28 May 2025

Healthcare

Avacta (LSE:AVCT) Reports Clinical Progress and Board Changes Ahead of AGM

Spire Healthcare Earns Double BUY Ratings with Up to 31% Upside Potential

Avacta Therapeutics Reports FY24 Results, Sharpens Focus on Oncology Drug Development

Dr. Martens Charts Path to Profit Recovery in FY26 Following Strategic Reset

hVIVO Faces Contract Cancellation and Trial Postponement Amid Sector Uncertainty

ANGLE Reports FY2024 Results with Narrowed Loss and Continued Focus on Pharma Collaborations

Poolbeg Pharma Gains FDA Orphan Drug Status for Groundbreaking CRS Prevention Treatment

Poolbeg Pharma Raises £4.87M to Advance Clinical Trials, Extends Cash Runway to 2027

IXICO Releases First-Half Results, On Track to Exceed 2025 Expectations

Poolbeg Pharma Launches £4.1 Million Fundraise to Advance Cancer and Obesity Treatments

Latest News

FORT Shares Climb 5%: Is Fort Technology Starting a New Momentum Run?

GFR Shares Climb 3%: Is Greenfire Resources Heating Up With Energy Buyers?

FTG Stock Climbs 4%: Is Firan Technology Group Back in Growth Mode?

FISH Stock Climbs 4%: Is Sailfish Royalty’s Precious-Metals Exposure Attracting Buyers?

GAU Shares Gain 3%: Is Galiano Gold Joining the Precious-Metals Rally?

EOG Stock Rises 5%: Is Eco Atlantic Back in Energy Investors’ Sights?